Online inquiry

IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14084MR)

This product GTTS-WQ14084MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets DLL4 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_019074.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 54567
UniProt ID Q9NR61
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ14084MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2034MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AHLX-20
GTTS-WQ11827MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MK-4280
GTTS-WQ12477MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA NN-8226
GTTS-WQ14611MR IVTScrip™ mRNA-Anti-DLL3, SC0001(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SC0001
GTTS-WQ1148MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABP 215
GTTS-WQ11566MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MG-A271
GTTS-WQ369MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ15526MR IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA UCB-7858
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW